Institute for Health and Care Excellence (NICE) has published
its Final Guidance on the use of
brodalumab (Kyntheum) for severe psoriasis in England and Wales.
is recommended to treat severe psoriasis, where people have not had adequate
results from conventional systemic treatments, or cannot take
blocks the activity of interleukin 17A (IL-17A), a chemical ’messenger’ in the
immune system that signals other cells to cause inflammation. In people with
psoriasis the immune system is overactive and creates too much inflammation,
which leads to the development of psoriasis symptoms. By blocking IL-17A,
Kyntheum aims to prevent some of that inflammation from occurring, leading to
an improvement in psoriasis for some people who take it. Other biologic
medications that block the activity of IL-17A, called Cosentyx (secukinumab) and Taltz (ixekizumab) are
currently available for people with severe psoriasis.
We will be publishing more information on brodalumab
(Kyntheum) for psoriasis soon. In the meantime, please get in touch with us if you have any questions.